GLP-1 Clinical Trials Explained: SURMOUNT, STEP, and Beyond

The Science Behind the Results

The remarkable weight loss results of GLP-1 therapy aren't anecdotal — they're backed by some of the most rigorous clinical trials in obesity research history.

STEP Trials (Semaglutide)

The Semaglutide Treatment Effect in People with Obesity (STEP) program comprised four pivotal trials:

• STEP 1 (n=1,961): 14.9% average weight loss at 2.4mg over 68 weeks
• STEP 2 (n=1,210): 9.6% in patients with type 2 diabetes
• STEP 3 (n=611): 16.0% with intensive behavioral therapy
• STEP 4 (n=902): Demonstrated weight regain after discontinuation

SURMOUNT Trials (Tirzepatide)

The SURMOUNT program established Tirzepatide as the most effective GLP-1 therapy:

• SURMOUNT-1 (n=2,539): 15mg dose achieved 22.5% weight loss over 72 weeks
• SURMOUNT-2 (n=938): 14.7% in type 2 diabetes patients
• SURMOUNT-3: 26.6% with intensive lifestyle intervention
• SURMOUNT-4: Confirmed weight regain upon discontinuation

Key Takeaways

1. Both medications show dose-dependent weight loss — higher doses produce more results
2. Tirzepatide consistently outperforms Semaglutide by 5-8 percentage points
3. Weight maintenance requires ongoing therapy — most weight is regained within a year of stopping
4. Both medications show significant improvements in cardiometabolic markers (A1c, blood pressure, cholesterol)
5. Side effects are primarily GI-related and decrease over time

What This Means for You

These aren't small studies — they involve thousands of participants across diverse populations. The data strongly supports GLP-1 therapy as one of the most effective non-surgical interventions for obesity in medical history.